LifeMD (NASDAQ: $LFMD (LifeMD Inc)) Investment Analysis Summary
Company Overview
LifeMD, founded in 2016 and based in New York, is a telehealth platform offering virtual consultations, prescriptions, and chronic care via its LifeMD Plus subscription. Services include 24/7 urgent/primary care, mental health, and weight management with GLP-1 drugs like Wegovy (as low as $0 copay). It integrates an in-house pharmacy for efficiency and features brands like Rex MD for men's health. As of June 30, 2025, it has 725,000+ members, 1M+ consultations, and 297,000 active patients, with a 4.9-star satisfaction rating.
Recent Performance and 2025 Guidance
Q1 2025 revenues jumped 49% to $65.7M, achieving positive GAAP EPS. Q2 telehealth grew 30% with 89% gross margins, but higher acquisition costs and Rex MD issues caused a 40% stock drop. Full-year guidance revised to $250–$255M from $268–$275M. Shares trade at ~$5.80 (Sept. 15, 2025), down 5% weekly but rebounding from lows. Q3 expected to show recovery via positive cash flow.
Key Strategies for Growth
Focus on weight management in the obesity market, plus expansions in chronic care (sleep, mental health) and Medicare. Pharmacy integration targets 89% margins and 30%+ revenue growth through subscriptions and retention. 25% insider ownership aligns incentives in the $100B+ telehealth space.
Challenges and Risks
August 2025 class-action lawsuit alleges misleading statements on obesity/Rex MD, fueling a 44% drop. Risks include telemedicine/GLP-1 regulations, competition from Hims & Hers, net losses (P/E -39), high marketing ($26M/quarter), and volatility (beta 1.57). Broader sector pressures add uncertainty.
Valuation and Outlook
$279M market cap at 1.2x P/S (EV/S ~1.0x) undervalues vs. peers. "Buy" consensus with $12.50 target (115%+ upside; high $18). Near 52-week low, but Q3 beat could reverse trend. Smaller scale vs. HIMS offers high growth potential.
Investment Thesis
LifeMD taps telehealth boom, especially GLP-1 demand, with 89% margins and profitability path. Recent dips from guidance/legal issues undervalue its trajectory. Ideal for risk-tolerant investors seeking 100%+ returns, but diversify due to competition and regulations.... Show More
Not investment advice. The author may have financial interests in the mentioned instruments.
We use our own and third-party cookies on our websites to enhance your experience, analyze traffic, and for security and marketing. For more info, see our Cookie Policy or go to Manage Settings.
Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information
Manage Consent Preferences
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookie List
label
ConsentLeg.Interest
label
label
label
Fri May 15 2026 04:43:40 GMT+0000 (Coordinated Universal Time)
